Sensus Healthcare, Inc.: directors' dealings · United States · SEC (Form 4)

About Sensus Healthcare, Inc.

Sensus Healthcare, Inc. is a US medical-device company listed on the Nasdaq market in the United States under the ticker SRTS. Headquartered in Boca Raton, Florida, the business was organized in 2010 and later completed its corporate conversion into Sensus Healthcare, Inc. in 2016. The company is highly focused: it designs, manufactures, and commercializes superficial radiation therapy (SRT) systems used primarily for non-melanoma skin cancers and, in certain cases, non-oncological dermatological conditions such as keloids. That narrow focus makes Sensus an interesting small-cap medtech name: it has a differentiated technology platform, but its investment case is highly sensitive to reimbursement, physician adoption, and customer concentration. Its core product family consists of the SRT-100, SRT-100+, and SRT-100 Vision platforms. The SRT-100 Vision, also known as IG-SRT, integrates high-frequency ultrasound imaging into the treatment workflow to improve targeting and treatment planning. Beyond the hardware itself, Sensus has been building a broader clinical ecosystem around its devices, including workflow tools, records management, reimbursement support, and, since 2024, a healthcare-services subsidiary supporting dermatology clinics through equipment, radiation oncology oversight, physics oversight, and on-site technologist services under its “Fair Deal Agreement” model. From a competitive standpoint, Sensus is best viewed as a niche specialist rather than a broad-based market leader. Its value proposition centers on a non-invasive, patient-friendly alternative to surgery that aims to reduce pain, scarring, and recovery time. Commercial success therefore depends not only on clinical performance, but also on the willingness of dermatology and oncology practices to adopt the technology, the strength of reimbursement, and the company’s ability to expand and retain its installed base. The company operates globally as a single reportable segment and sells through a distribution and marketing network, with exposure to the United States and select international markets, including China. Recent developments have been important for the investment narrative. Throughout 2025 and into early 2026, Sensus highlighted improving reimbursement visibility, including the publication of dedicated CPT codes for superficial radiotherapy for non-melanoma skin cancer. Management has described this as a meaningful catalyst for customer activity, diversification, and eventual profitability. In February 2026, the company launched Sensus Link, a cloud-based software and connectivity solution designed to extend capabilities across its installed base. In first-quarter 2026 reporting, Sensus emphasized a cash balance of $18.3 million and no debt, which is notable for investors following this Nasdaq-listed United States medtech company.